CA-LONG-TALE-GAMES
18.4.2024 14:01:33 CEST | Business Wire | Press release
Long Tale Games (LTG) announces the Steam relaunch of Life is Feudal: MMO. To show appreciation to the game's community, the publisher is launching a special event aimed at the game's original players, the Balance Restoration Campaign. Players who have made any purchases during the previous Life is Feudal: MMO round will receive special LiF Coins that can be exchanged for a subscription to the game.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240418169927/en/
(Graphic: Business Wire)
Since the relaunch in June 2023, Life is Feudal: MMO has transitioned to a subscription-based model, removing all pay-to-win features. This shift ensures a level playing field for all players, fostering fairness as success in the game now fully depends on the player's skill and effort, creating a more engaging environment. Until now, the game has only been distributed through the publisher's (LTG.com) own personal gaming platform. However, with this launch, it is now expanding its presence to other stores, starting with Steam.
Evgenii Romin, Publishing Director at Long Tale Games, expressed his enthusiasm for the forthcoming relaunch and the accompanying campaign by saying, "We are incredibly excited to introduce 'Life is Feudal: MMO' to a broader audience via Steam. In addition, we're eager to show our gratitude towards our community through the balance restoration campaign. This endeavor demonstrates our appreciation for our players' support and mirrors our dedication to ensuring a fair and rewarding gaming experience."
Life is Feudal: MMO has been significantly refined through relentless development, targeted rebalancing, and the elimination of bugs while maintaining a strong bond with its community, with a special nod to the contributions of modders. The game has experienced a renaissance with over 150 updates to its content, including new items, buildings, professions, and gameplay mechanics, along with the introduction of much-anticipated features like in-game voice chat, anti-cheat systems, and additional content. These advancements and captivating events, such as the King of the Hill competition, have profoundly enriched the gaming experience. Thank you to the players and the MMO community for their dedication to our favorite real-life Medieval simulator.
Looking ahead, the roadmap for Life is Feudal: MMO includes major updates inspired by the community's feedback, such as a new map and many game improvements scheduled for mid-2024. This strategy underscores LTG's commitment to developing Life is Feudal: MMO in close cooperation with the community.
What is Life is Feudal: MMO?
Life is Feudal: MMO is a sandbox MMORPG set in a gritty medieval world called Abella. Players find themselves in this strange new world with no memory of their past and must quickly learn the basics of survival, from hunting and gathering to finding allies who will support them in their time of need. As their journey progresses, players will be able to learn new skills that allow them to craft intricate weapons, construct buildings, and even establish towns, castles, and mighty fortresses.
Whether players choose to band together in guilds and march out on epic wars of conquest or master the art of solo survival, the game offers endless opportunities for explorations and conquest, no matter what path they set out on.
About Long Tale Games
Long Tale Games (LTG) is a multiverse publisher set on reinvigorating legendary games with fresh energy and employing innovative monetization and user acquisition techniques. With a diverse portfolio that includes everything from classic to web3 games, LTG leverages industry expertise to channel, port, further develop, and support the marketing of hidden gems and classics, ensuring each project gets a tailored approach. At its core, LTG is powered by dedicated industry veterans who believe in a community-driven strategy, involving players in the development process to breathe new life into every game, proving their dedication to reviving beloved titles and fostering the growth of new ventures in the gaming world.
For additional information and to learn more, please visit corp.ltg.com
The monetization model: $14.99 monthly subscription, with a 7-day free trial for new users and 30 days for owners of the original Life is Feudal: MMO on Steam.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240418169927/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Murata Launches Ultra-Low Power AMR Sensors to Boost Battery Life in Healthcare and Wearables Devices27.4.2026 04:00:00 CEST | Press release
Murata Manufacturing Co., Ltd. (TOKYO: 6981) (ISIN: JP3914400001) has commenced mass production of its MRMS166R and MRMS168R anisotropic magnetoresistance (AMR) sensors for healthcare, wearable, and IoT devices. The MRMS166R is the first AMR sensor to combine an average current consumption of 20 nA with operation from a 1.2 V supply, enabling extended battery life in coin cell-powered systems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260413296947/en/ [Murata Manufacturing Co., Ltd.] AMR sensor The devices are solid-state magnetic sensors used for switching applications. They detect the presence or absence of a magnetic field and generate an output signal that system logic uses to control functions such as transitions between active and sleep modes. This enables contactless switching without mechanical components, improving reliability, and supporting sealed, miniaturized designs. Automatic switching between active and
Sun Pharma signs Definitive Agreement to Acquire Organon27.4.2026 01:51:00 CEST | Press release
Organon stockholders to receive US$ 14.00 per share in cashThe deal values Organon at EV of US$ 11.75 billionCombined Business leverages complementary portfolios and global scale for sustained long‑term value creation Sun Pharmaceutical Industries Limited(Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) (together with its subsidiaries and/or associated companies, “Sun Pharma”) and Organon & Co. (NYSE: OGN) (“Organon”) today announced that they have entered into a definitive agreement under which Sun Pharma will acquire all outstanding shares of Organon for US$ 14.00 per share in an all‑cash transaction with an enterprise valuation of US$ 11.75 billion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260426881370/en/ Organon is a global healthcare company formed through a spinoff from Merck, known as MSD outside of the United States and Canada, in 2021. Organon has a legacy of deep trust and strong brand equit
Andersen Global udvider sin tilstedeværelse i Afrika med lanceringen af medlemsfirma i Cameroun26.4.2026 20:56:00 CEST | Pressemeddelelse
Andersen Global træder ind på det camerounske marked, idet Phoenix Advisory bliver medlemsfirma og overgår til Andersen-brandet. Andersen in Cameroun er et specialiseret rådgivningsfirma, der leverer strategiske, erhvervsmæssige, finansielle og operationelle rådgivningsydelser til organisationer i forskellige vækstfaser. Firmaet er grundlagt af fagfolk med erfaring fra store internationale organisationer og kombinerer et stærkt lokalt og centralafrikansk funderet kendskab til forretningsmæssige, juridiske og skattemæssige regler med en skræddersyet tilgang, der har til formål at skabe konkrete og målbare resultater for klienterne. "Overgangen til Andersen-brandet afspejler vores engagement i at vokse sammen med vores kunder og imødekomme stadig mere komplekse behov," udtalte administrerende partner Albert Désiré Zang. "Vi tror på, at langsigtet succes skabes gennem tillid, kvalitet og vedvarende support. At blive et medlemsfirma styrker vores evne til at levere gennemtænkte, bæredygtig
PMCOrganometallix Announces Price Increase on All Products24.4.2026 22:55:00 CEST | Press release
Due to significant changes in market conditions, PMC Organometallix, Inc. announces that effective May 1, 2026, or as contracts permit, prices across all product lines globally will increase by 10-25%. This adjustment is driven by sustained cost pressures from key inputs including rising raw material costs and escalating freight and logistics expenses. While the company has been absorbing these increases, the current economic environment brought on by the geopolitical crisis of the Iran conflict requires this adjustment to continue providing the high-quality, consistent materials and supply reliability that customers expect. PMC Organometallix will implement these changes in a transparent, collaborative manner and values your partnership while navigating these economic challenges. Customers with questions or to discuss a specific situation should contact their account representative. About PMC Group PMC Group is a growth-oriented, diversified, global chemicals and plastics company deli
Frankfurt Higher Regional Court upholds BESREMi® arbitral award in favor of AOP Health24.4.2026 18:52:00 CEST | Press release
Today, the Higher Regional Court of Frankfurt upheld the February 20251 partial final ICC arbitral award in favor of AOP Orphan Pharmaceuticals GmbH (“AOP Health”) in its dispute with PharmaEssentia Corp. (“PharmaEssentia”). The ruling confirms the award which found the Taiwanese company to be liable for certain damages. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260424005227/en/ Portrait Dr. Rudolf Widmann, Founder AOP Health Credit: AOP Health/Daniel Ospelt Dr. Rudolf Widmann, one of the two founders of AOP Health, explains: “We very much welcome the Frankfurt Higher Regional Court’s decision that confirms our position. In the interest of our patients, we are dedicated to maintaining stable and sustainable access to BESREMi® and to responsibly navigating future challenges.” The Product in Dispute The conflict centers around BESREMi® (ropeginterferon alfa-2b), a product launched in 2019 and developed by AOP Health into
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
